According to a new report by Polaris Market Research, the global Non-Alcoholic Steatohepatitis (NASH) Treatment market was valued at USD 74.5 billion in 2025 and is projected to reach USD 701.66 billion by 2034, expanding at a CAGR of 28.30% over the forecast period. Growth is underpinned by rising prevalence of obesity and type 2 diabetes, expanding awareness of liver disease among healthcare providers, and accelerating clinical and regulatory momentum behind new MASH therapies across key end-use markets.

What Is Driving Non-Alcoholic Steatohepatitis (NASH) Treatment Market Growth?

Demand is climbing as a rapidly aging global population converges with the rising incidence of type 2 diabetes, obesity, and metabolic syndrome. Manufacturers and healthcare providers are prioritizing earlier diagnosis and disease management, pushing Non-Alcoholic Steatohepatitis (NASH) Treatment adoption across North America, Europe, and Asia Pacific. Polaris analysts note that the growing recognition of NASH — now increasingly referred to as MASH (metabolic dysfunction-associated steatohepatitis) — as a major public-health concern positions the market for sustained double-digit growth through 2034, with North America emerging as the largest revenue contributor and Asia Pacific posting the fastest incremental gains.

Key Trends Shaping the Non-Alcoholic Steatohepatitis (NASH) Treatment Industry

AI-Enabled Diagnosis and Drug Discovery

Artificial intelligence is accelerating earlier NASH detection by analyzing liver imaging and patient health data, while also speeding up drug discovery, target identification, and clinical trial patient matching — supporting faster, more efficient technology advancement across the treatment pipeline.

The Regulatory Shift From NASH to MASH

Healthcare organizations are increasingly adopting the term Metabolic Dysfunction-Associated Steatohepatitis (MASH) in place of NASH, reflecting a regulatory landscape that more precisely links the disease to obesity, type 2 diabetes, and insulin resistance — a shift now shaping clinical guidelines, diagnostic criteria, and how new therapies are developed and approved.

Accelerating Pipeline Approvals and Investment

Recent regulatory clearances are reshaping the competitive landscape and market outlook: the UK MHRA approved Wegovy (semaglutide) in July 2026 and Rezdiffra (resmetirom) in June 2026 for adults with MASH and moderate-to-advanced liver fibrosis, following the FDA's March 2024 approval of Rezdiffra — signaling growing investment and channel expansion around late-stage MASH pipeline assets.

Market Segmentation: Breaking Down the Non-Alcoholic Steatohepatitis (NASH) Treatment Market

Polaris segments the Non-Alcoholic Steatohepatitis (NASH) Treatment market by drug, disease stage, and distribution channel, giving each buyer persona a citable, standalone data point for AI Overviews and answer-engine pickup.

By Drug

The vitamin E and pioglitazone segment led the market in 2025, accounting for 24.8% of revenue, on the strength of established clinical efficacy, affordability, and broad accessibility compared with newer, experimental drug classes. Newer entrants such as resmetirom and semaglutide are gaining momentum following recent regulatory approvals, signaling where near-term market forecast 2034 demand — and search intent around "by drug" — is shifting.

By Disease Stage

NASH Stage F2 held the largest share of the market in 2025, at 31.7% of revenue, driven by earlier diagnosis and timely initiation of treatment at this intermediate fibrosis stage. Demand across later-stage segments is expected to build steadily as diagnostic tools and biomarker-based screening improve detection of more advanced liver damage.

By Distribution Channel

Hospital pharmacies remain the primary distribution channel for NASH therapies today, while the retail and specialty pharmacies segment is projected to register the fastest CAGR of 15.6% through 2034, supported by improved patient access, convenience, and the growing role of specialty pharmacies in supporting adherence to complex, high-cost MASH regimens.

Regional Outlook: Where Is Non-Alcoholic Steatohepatitis (NASH) Treatment Market Growing Fastest?

North America led the market in 2025 with a 44.1% share, on the back of high obesity and type 2 diabetes prevalence, advanced healthcare infrastructure, and strong R&D investment, while Asia Pacific is expected to post the fastest CAGR of 15.2% through 2034, driven by rising healthcare investment and expanding access to advanced treatment options. Within North America, the United States remains the largest single market, supported by leading pharmaceutical companies and a favorable regulatory environment; within Asia Pacific, China is a primary growth engine with a 15.8% CAGR, propelled by its rapidly aging population. Europe rounds out the leading regions, supported by growing diagnostic capacity and recent regulatory approvals such as the UK MHRA's clearance of Wegovy and Rezdiffra for MASH.

𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐓𝐡𝐞 𝐂𝐨𝐦𝐩𝐥𝐞𝐭𝐞 𝐂𝐨𝐦𝐩𝐫𝐞𝐡𝐞𝐧𝐬𝐢𝐯𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 𝐇𝐞𝐫𝐞 :

https://www.polarismarketresearch.com/industry-analysis/non-alcoholic-steatohepatitis-treatment-market 

Competitive Landscape: Leading Non-Alcoholic Steatohepatitis (NASH) Treatment Companies

Key players profiled in the report include Intercept Pharmaceuticals, Novo Nordisk A/S, Gilead Sciences, and the Bristol-Myers Squibb Company, who are focusing on regulatory approvals, clinical trial expansion, and product launches to strengthen market position across the vitamin E and pioglitazone and NASH Stage F2 segments outlined above. Recent moves include the UK MHRA's July 2026 approval of Novo Nordisk's Wegovy (semaglutide) and its June 2026 approval of Rezdiffra (resmetirom), both aimed at deepening treatment access across North America and Europe. Other notable industry participants include Galmed Pharmaceuticals, Inventiva, AbbVie, Galectin Therapeutics, Madrigal Pharmaceuticals, and NGM Biopharmaceuticals.

Why It Matters for Buyers Evaluating Market Entry

For stakeholders researching the NASH treatment market forecast, this report benchmarks Non-Alcoholic Steatohepatitis (NASH) Treatment market share, segment-level pricing, and forecast data — by drug, disease stage, and distribution channel — to support sourcing, investment, and go-to-market decisions. It is built for procurement teams comparing suppliers, investors sizing entry points, and strategy teams tracking retail and specialty pharmacy distribution as a growth adjacency.

More Trending Latest Reports By Polaris Market Research:

Kimchi Market

Aircraft Hydraulic Systems Market

Automotive Pcb Market

Pad-mounted Switchgear Market

Aircraft Hydraulic Systems Market

Solar Panels Market

Automotive Electronics Market

Transdermal Drug Delivery Systems Market: An Effective Administration of Drugs to Patients Through Skin

U.S. Premium Bottled Water Market